In recent work, an AF PGS was shown to enhance risk prediction when added to clinical models such as HARMS2-AF (AUROC: 0.828 to 0.839) and CHARGE-AF (0.808 to 0.828) in population-based cohorts like UK Biobank14, and in a clinical cohort of cardiovascular disease patients, where combining an AF PGS with CHARGE-AF and NT-proBNP improved the C-index from 0.67 to 0.7054. Here, NPPB is linked to cardiovascular disorder.